Patents Assigned to HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
  • Patent number: 11261196
    Abstract: A salt serving as an Akt inhibitor and a crystal thereof, specifically related to a salt of the compound of formula (I) and a crystal thereof.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 1, 2022
    Assignee: HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
    Inventors: Gang Li, Lun Lu, Qingqing Lu, Lihong Hu, Charles Z. Ding
  • Patent number: 11078194
    Abstract: Disclosed in the present invention are a salt form and a crystal form serving as FGFR and VEGFR inhibitor compounds, a preparation method therefor, and medical uses thereof.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: August 3, 2021
    Assignee: HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
    Inventors: Zhengxia Chen, Yang Zhang, Meibi Dai, Hongfei Cheng, Suqin Yang, Wenju Li, Jian Li, Shuhui Chen
  • Patent number: 10654868
    Abstract: Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: May 19, 2020
    Assignee: HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
    Inventors: Lun Lu, Zhibo Zhang, Gang Li, Lihong Hu, Charles Z. Ding, Shuhui Chen
  • Patent number: 10519133
    Abstract: FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: December 31, 2019
    Assignees: MEDSHINE DISCOVERY INC., HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
    Inventors: Shuhui Chen, Zhengxia Chen, Meibi Dai, Cheng Xie, Peng Li, Yang Zhang, Guibai Liang, Qiang Wang, Jiangpeng Liao, Fei Sun, Guoping Hu, Jian Li